English
SpanishTrusted Resources: Community Center
Online groups, photo galleries and blogs
Patient of the Month: Gianna
After noticing that her daughter was unable to crawl, stand, or do the things her friend’s children were doing at six months of age, Idalmis decided that it was time to seek help. Sure enough, after some consultations and genetic testing, Idalmis’ gut feeling was right.
Her baby girl, Gianna, was diagnosed with spinal muscular atrophy type 2 (SMA2), a genetic neuromuscular disorder that affects the nerve cells that control voluntary muscles (motor neurons). Without treatment, progressive muscle weakness develops in babies with SMA2 between ages 6 and 12 months.
BookmarkRelated Content
-
Pharmacological and Clinical Profile of Onasemnogene Aveparvovec, the First Gene Therapy for Spinal Muscular Atrophy...Onasemnogene abeparvovec (Zolgensma; for...
-
Spinal Muscular Atrophy Type 2 (Intermediate SMA)Spinal muscular atrophy (SMA) is a genet...
-
Safety and Efficacy of Once-Daily Risdiplam in Type 2 and Non-Ambulant Type 3 Spinal Muscular Atrophy (SUNFISH Part ...Background: Risdiplam is an oral small m...
-
New Treatment Can Help Fresno Infant With Rare Genetic DisorderA Fresno family is holding onto hope aft...
-
Revised Upper Limb Module in Type II And III Spinal Muscular Atrophy: 24-Month ChangesThe aim of the study was to establish 24...
-
A Caregiver’s Guide to ZolgensmaIndication ZOLGENSMA® (onasemnogene abe...
-
Sleep Breathing Disorders in Pediatric Patients With Spinal Muscular Atrophy 2Objectives: The study is aimed to analyz...
